That's OK as far as it goes, but Dr T has pointed out that Pillar 1 is all cancers with overexpressed FTO, and that it makes no sense to value that pillar using only the two cancers which happen to have been chosen for the P2 PoC trials. In this pillar, either the drug will be effective for all cancers with overexpressed FTO or none of them.
MST valuation of RAC, page-39
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.65 | $179.8K | 108.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1437 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 3313 | 1 |
View Market Depth
| Last trade - 15.58pm 03/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |